AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA
AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA
